Contrasting Palvella Therapeutics (NASDAQ:PVLA) and Allogene Therapeutics (NASDAQ:ALLO)

Allogene Therapeutics (NASDAQ:ALLO) and Palvella Therapeutics (NASDAQ:PVLA) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends and earnings.

Analyst Recommendations

This is a summary of recent recommendations for Allogene Therapeutics and Palvella Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1	3	8	1	2.69
Palvella Therapeutics	1	0	12	2	3.00

Allogene Therapeutics presently has a consensus price target of $8.30, indicating a potential upside of 366.29%. Palvella Therapeutics has a consensus price target of $209.14, indicating a potential upside of 39.31%. Given Allogene Therapeutics’ higher probable upside, equities research analysts plainly believe Allogene Therapeutics is more favorable than Palvella Therapeutics.

Institutional and Insider Ownership

83.6% of Allogene Therapeutics shares are held by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are held by institutional investors. 13.2% of Allogene Therapeutics shares are held by insiders. Comparatively, 17.2% of Palvella Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Allogene Therapeutics and Palvella Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$4.64 million	132.54	-$190.89 million	($0.67)	-2.66
Palvella Therapeutics	N/A	N/A	-$41.72 million	($4.83)	-31.08

Palvella Therapeutics has lower revenue, but higher earnings than Allogene Therapeutics. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Allogene Therapeutics has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500. Comparatively, Palvella Therapeutics has a beta of -0.25, suggesting that its share price is 125% less volatile than the S&P 500.

Profitability

This table compares Allogene Therapeutics and Palvella Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-50.04%	-36.74%
Palvella Therapeutics	N/A	-47.84%	-38.33%

Summary

Allogene Therapeutics beats Palvella Therapeutics on 7 of the 13 factors compared between the two stocks.

About Allogene Therapeutics

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

About Palvella Therapeutics

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.